BridgeBio Pharma BBIO Gain (loss) on extinguishment of debt
Gain (loss) on extinguishment of debt at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:GainsLossesOnExtinguishmentOfDebt.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's gain (loss) on extinguishment of debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's gain (loss) on extinguishment of debt?
- BridgeBio Pharma (BBIO) reported gain (loss) on extinguishment of debt of $0 in Q1 2026.
- How has BridgeBio Pharma's gain (loss) on extinguishment of debt changed year-over-year?
- BridgeBio Pharma's gain (loss) on extinguishment of debt increased by 100.0% year-over-year, from -$21.16M to $0.
- What is the long-term trend for BridgeBio Pharma's gain (loss) on extinguishment of debt?
- Over 4 years (2021 to 2025), BridgeBio Pharma's gain (loss) on extinguishment of debt has grown at a 58.7% compound annual growth rate (CAGR), from -$3.34M to -$21.16M.
- What does gain (loss) on extinguishment of debt mean?
- The profit or loss realized when the company pays off debt earlier than its scheduled maturity date.
- How do you interpret gain (loss) on extinguishment of debt?
- A gain suggests the company retired debt at a discount, while a loss reflects a premium paid to exit debt early.
- How does gain (loss) on extinguishment of debt compare across companies?
- Standard across capital-intensive industries managing long-term debt portfolios.